AI assistant
Sending…
NovoCure Ltd — Director's Dealing 2022
Dec 5, 2022
31949_dirs_2022-12-05_7948edaf-9e83-4b57-abde-ccb6cf7b1efb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2022-12-02
Reporting Person: Cordova Ashley (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-12-02 | Ordinary Shares | M | 2000 | $7.15 | Acquired | 74376 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-12-02 | Options to Buy Ordinary Shares | $7.15 | M | 2000 | Disposed | 2027-02-21 | Ordinary Shares (2000.0) | Direct |
Footnotes
F1: Fully vested as of the date hereof.
More from NovoCure Ltd
Proxy Solicitation & Information Statement
2026
May 21
Regulatory Filings
2026
Apr 30
Interim / Quarterly Report
2026
Apr 30
Regulatory Filings
2026
Apr 24
Regulatory Filings
2026
Apr 9
Major Shareholding Notification
2026
Mar 26
Regulatory Filings
2026
Mar 26
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3